Joseph Oliveto
Vermögen: 633 666 $ am 31.05.2026
Vermögen: 633 666 $ am 31.05.2026
Mr. Joseph G.
Oliveto is a President & Chief Executive Officer at Milestone Pharmaceuticals USA, Inc. and a President, Chief Executive Officer & Director at Milestone Pharmaceuticals, Inc. He is on the Board of Directors at Milestone Pharmaceuticals, Inc. Mr. Oliveto was previously employed as a Chief Executive Officer & Director by Galleon Pharmaceuticals, Inc., a President, Chief Executive Officer & Director by Chelsea Therapeutics International Ltd., an Executive-in-Residence by A. M.
Pappas & Associates LLC, and a Director-Global Alliance by Hoffmann-La Roche, Inc. He received his undergraduate degree from Rutgers State University of New Jersey and an MBA from Rutgers State University of New Jersey.
| Unternehmen | Datum | Anzahl der Aktien | Bewertung | Datum der Bewertung |
|---|---|---|---|---|
| 16.04.2026 | 446.244 ( 0,36 % ) | 633 666 $ | 31.05.2026 |
| Unternehmen | Position | Beginn |
|---|---|---|
| MILESTONE PHARMACEUTICALS INC. | Vorstandsvorsitzender | 07.03.2017 |
Milestone Pharmaceuticals USA, Inc.
Milestone Pharmaceuticals USA, Inc. Pharmaceuticals: MajorHealth Technology Develops cardiovascular drugs | Vorstandsvorsitzender | 07.03.2017 |
| Unternehmen | Position | Ende |
|---|---|---|
Galleon Pharmaceuticals, Inc.
Galleon Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Develops and manufactures medicines for breathing-control conditions | Vorstandsvorsitzender | 01.06.2016 |
| CHELSEA THERAPEUTICS INTERNATIONAL LTD. | Vorstandsvorsitzender | 23.06.2014 |
Pappas Capital LLC
Pappas Capital LLC Investment ManagersFinance Pappas Ventures invests in companies located in the across the globe and primarily in United States, Canada and Asia. The firm focuses on next-generation life science, agriculture, and technology. It participates in seed and early-stage transactions. | Corporate Officer/Principal | 30.06.2008 |
Hoffmann-La Roche, Inc.
Hoffmann-La Roche, Inc. BiotechnologyHealth Technology Operates as a biotech company that develops pharmaceutical and diagnostic solutions | Corporate Officer/Principal | 01.01.2008 |
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
| Private Unternehmen | 7 |
|---|---|
Chelsea Therapeutics International Ltd.
Chelsea Therapeutics International Ltd. Pharmaceuticals: MajorHealth Technology Operates as a pharmaceutical company developing and commercializing therapeutics for a variety of human diseases | Health Technology |
Galleon Pharmaceuticals, Inc.
Galleon Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Develops and manufactures medicines for breathing-control conditions | Health Technology |
Milestone Pharmaceuticals, Inc.
Milestone Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Develops and manufactures cardiovascular medicines | Health Technology |
Hoffmann-La Roche, Inc.
Hoffmann-La Roche, Inc. BiotechnologyHealth Technology Operates as a biotech company that develops pharmaceutical and diagnostic solutions | Health Technology |
Pappas Capital LLC
Pappas Capital LLC Investment ManagersFinance Pappas Ventures invests in companies located in the across the globe and primarily in United States, Canada and Asia. The firm focuses on next-generation life science, agriculture, and technology. It participates in seed and early-stage transactions. | Finance |
Rutgers State University of New Jersey
Rutgers State University of New Jersey Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Milestone Pharmaceuticals USA, Inc.
Milestone Pharmaceuticals USA, Inc. Pharmaceuticals: MajorHealth Technology Develops cardiovascular drugs | Health Technology |
Bitte wählen Sie Ihre Ausgabe
Alle länderspezifischen Finanzinformationen